Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADC Therapeutics's ROE % for the quarter that ended in Mar. 2026 was 0.00%. ADC Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was N/A.
ADC Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.
ADC Therapeutics ROE % Adjusted to Book Value Related Terms
ADC Therapeutics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for ADC Therapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADC Therapeutics ROE % Adjusted to Book Value Chart
ADCT vs GNLX, VXRT, COYA: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ADC Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADC Therapeutics ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ADC Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where ADC Therapeutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 0.00% mean?
ADC Therapeutics (ADCT) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ADC Therapeutics and its competitors.
Is ADC Therapeutics' ROE % Adjusted to Book Value too high?
ADC Therapeutics' current ROE % Adjusted to Book Value is 0.00%. Overall, ADC Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ADC Therapeutics' ROE % Adjusted to Book Value compare to GNLX and VXRT?
ADC Therapeutics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on ADC Therapeutics and its competitors. ADC Therapeutics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, ADC Therapeutics (ADCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.09, compared to a current price of $1.26 — trading 39.7% below its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. ADC Therapeutics' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For ADC Therapeutics (ADCT), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADC Therapeutics (ADCT) Overvalued in 2026?
Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued.
The current stock price of $1.26 is trading 39.7% below its estimated GF Value™ of $2.09.
GuruFocus considers ADC Therapeutics to be Possible Value Trap.
Key valuation signals for ADCT:
ROE % Adjusted to Book Value: 0.00%
GF Value™: $2.09 vs. price of $1.26 (39.7% below fair value)
No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
41GF Score
Get the complete analysis for ADCT
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCT has been successfully added to your 
